Drug intelligence / Profile preview

QDP102

Development stage: Preclinical
Lead developer: RestoriT

Overview

QDP102 is an investigational therapeutic candidate currently in development by RestoriT, specifically targeting diabetes supportive care. As part of RestoriT's pipeline of 'Quality of Life' (QDP) products, QDP102 is designed to address the unmet needs of patients living with diabetes, likely focusing on managing complications or improving the tolerability of standard treatments. Detailed information regarding its specific mechanism of action, molecular target, and chemical modality remains proprietary and has not been disclosed in public pipeline listings as of early 2025. The asset is positioned as a restorative therapy intended to improve patient outcomes and quality of life alongside standard diabetic care.

Other names: QDP102-RestoriT-diabetes supportive careQDP-102-RestoriT-diabetes supportive careQDP 102-RestoriT-diabetes supportive care

Beyond the preview

Go deeper on QDP102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QDP102.

Explore the full profile